NeuroMetrix Continues to Soar on FDA's Breakthrough Designation for Quell; Shares Surge Early
NeuroMetrix () shares continue to soar in Wednesday trading, rising nearly 88% after gaining more than 200% a day earlier after the US Food and Drug Administration granted NeuroMetrix's Quell device breakthrough designation to treat fibromyalgia.
The FDA's Breakthrough Device Program will provide NeuroMetrix with priority review and interactive communication for device development, through to commercialization, the company said Tuesday. There are also government policies and programs under consideration that could facilitate Medicare reimbursement for FDA Breakthrough Devices following marketing authorization, it added.
Price: 18.86, Change: +8.82, Percent Change: +87.85